Overview

Effect of GSK704838 In Healthy Volunteers

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

GSK704838C is a potent, pan-active mAChR antagonist, which is being developed for once-daily treatment of chronic obstructive pulmonary disease (COPD).

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline